References
- Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007;76:481–511.
- Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am j Cardiol 1999;83:3C–12C.
- Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC et al. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479–488.
- Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009;8:3331–3340.
- Abadi AH, Abouel-Ella DA, Ahmed NS, Gary BD, Thaiparambil JT, Tinsley HN et al. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. Arzneimittelforschung 2009;59:415–421.
- Maw GN, Allerton CM, Gbekor E, Million WA. Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors. Bioorg Med Chem Lett 2003;13:1425–1428.
- Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD et al. Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. j Med Chem 2011;54:495–509.
- Yang GF, Huang X. Development of quantitative structure-activity relationships and its application in rational drug design. Curr Pharm Des 2006;12:4601–4611.
- Yang GF, Lu HT, Xiong Y, Zhan CG. Understanding the structure-activity and structure-selectivity correlation of cyclic guanine derivatives as phosphodiesterase-5 inhibitors by molecular docking, CoMFA and CoMSIA analyses. Bioorg Med Chem 2006;14:1462–1473.
- Chen G, Wang H, Robinson H, Cai J, Wan Y, Ke H. An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies. Biochem Pharmacol 2008;75:1717–1728.
- Chen CY, Chang YH, Bau DT, Huang HJ, Tsai FJ, Tsai CH et al. Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis. Acta Pharmacol Sin 2009;30:1186–1194.
- Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233–2247.
- MOE: Chemical Computing Group Inc. Montreal. H3A 2R7 Canada. http://www.chemcomp.com
- Jain AN. Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities. j Comput Aided Mol Des 1996;10:427–440.
- Cramer RD 3rd, Patterson DE, Bunce JD. Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 1989;291:161–165.
- Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. j Med Chem 1994;37:4130–4146.
- Sybyl-X 1.0. Tripos Inc 1699 South Hanley Road. St Louis. Missouri. 63144. USA.